Among New Drug Launches, Oncology Scores Big While CV Lags

28 Mar 2016
News

Jessica Merrill @Jessicaemerrill Jessica.merrill@informa.com

Executive Summary

Bristol’s Opdivo and Pfizer’s Ibrance are standouts among recent drug launches, well on their way to becoming commercial blockbusters, while new cardiovascular drugs like Repatha, Praluent and Entresto, forecast to become blockbusters in their own right, have been slow at launch, restrained by market access.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Subjects
Launches

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Launches

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS057538

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS057538

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Among New Drug Launches, Oncology Scores Big While CV Lags

News

Executive Summary

Related Content

Korea Green Light For Pfizer’s Novel Breast Cancer Drug

Pfizer Oncology Strategy: An Investment Starts To Pay Off

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert